SE8603582L - Komposition innehallande l-dopa - Google Patents

Komposition innehallande l-dopa

Info

Publication number
SE8603582L
SE8603582L SE8603582A SE8603582A SE8603582L SE 8603582 L SE8603582 L SE 8603582L SE 8603582 A SE8603582 A SE 8603582A SE 8603582 A SE8603582 A SE 8603582A SE 8603582 L SE8603582 L SE 8603582L
Authority
SE
Sweden
Prior art keywords
dopa
weight during
release
composition containing
accordance
Prior art date
Application number
SE8603582A
Other languages
English (en)
Other versions
SE8603582D0 (sv
SE460947B (sv
Inventor
C H Appelgren
E C Eskilsson
Original Assignee
Lejus Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lejus Medical Ab filed Critical Lejus Medical Ab
Priority to SE8603582A priority Critical patent/SE460947B/sv
Publication of SE8603582D0 publication Critical patent/SE8603582D0/sv
Priority to AT87850251T priority patent/ATE58292T1/de
Priority to ES198787850251T priority patent/ES2036221T3/es
Priority to EP87850251A priority patent/EP0260236B1/en
Priority to DE8787850251T priority patent/DE3766200D1/de
Priority to MX007910A priority patent/MX172918B/es
Priority to NO873589A priority patent/NO176549C/no
Priority to DK442287A priority patent/DK442287A/da
Priority to HU873749A priority patent/HU197211B/hu
Priority to CA000545254A priority patent/CA1298198C/en
Priority to DD87306327A priority patent/DD286107A5/de
Priority to FI873672A priority patent/FI86689C/sv
Priority to JP62210363A priority patent/JPH0662405B2/ja
Priority to PT85591A priority patent/PT85591B/pt
Publication of SE8603582L publication Critical patent/SE8603582L/sv
Priority to US07/378,423 priority patent/US4981695A/en
Publication of SE460947B publication Critical patent/SE460947B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Fats And Perfumes (AREA)
SE8603582A 1986-08-26 1986-08-26 En multiple-unit-dos komposition av l-dopa SE460947B (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE8603582A SE460947B (sv) 1986-08-26 1986-08-26 En multiple-unit-dos komposition av l-dopa
AT87850251T ATE58292T1 (de) 1986-08-26 1987-08-21 L-dopa enthaltendes arzneimittel.
ES198787850251T ES2036221T3 (es) 1986-08-26 1987-08-21 Procedimiento para preparar una composicion de l-dopa de dosis unitaria multiple.
EP87850251A EP0260236B1 (en) 1986-08-26 1987-08-21 Composition comprising l-dopa
DE8787850251T DE3766200D1 (de) 1986-08-26 1987-08-21 L-dopa enthaltendes arzneimittel.
FI873672A FI86689C (sv) 1986-08-26 1987-08-25 Förfarande för framställning av en multipel-unit-doskomposition, som i nnehåller L-dopa som farmaceutiskt aktiv substans
NO873589A NO176549C (no) 1986-08-26 1987-08-25 Fremgangsmåte for fremstilling av L-dopa-kjerner med 2 overtrekk
MX007910A MX172918B (es) 1986-08-26 1987-08-25 Composicion a base de l-3,4-dihidroxifenilalanina
DK442287A DK442287A (da) 1986-08-26 1987-08-25 Farmaceutisk praeparat indeholdende l-3,4-dihydroxyphenylalanin (l-dopa) som aktiv bestanddel og fremgangsmaade til fremstilling af et saadant praeparat
HU873749A HU197211B (en) 1986-08-26 1987-08-25 Process for producing pharmaceutical composition containing l-dopa as active component coated with coating for regulating release of the active components
CA000545254A CA1298198C (en) 1986-08-26 1987-08-25 Composition comprising l-dopa
DD87306327A DD286107A5 (de) 1986-08-26 1987-08-25 Zusammensetzung mit mehrfachdosierung, die als pharmazeutisch wirksame verbindung entfaellt
JP62210363A JPH0662405B2 (ja) 1986-08-26 1987-08-26 Ｌ―ドーパ含有組成物
PT85591A PT85591B (pt) 1986-08-26 1987-08-26 Processo para a preparacao de composicoes farmaceuticas sob a forma de dose unitaria-multipla contendo l-dopa
US07/378,423 US4981695A (en) 1986-08-26 1989-07-12 Composition comprising L-dopa

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8603582A SE460947B (sv) 1986-08-26 1986-08-26 En multiple-unit-dos komposition av l-dopa

Publications (3)

Publication Number Publication Date
SE8603582D0 SE8603582D0 (sv) 1986-08-26
SE8603582L true SE8603582L (sv) 1988-02-27
SE460947B SE460947B (sv) 1989-12-11

Family

ID=20365397

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8603582A SE460947B (sv) 1986-08-26 1986-08-26 En multiple-unit-dos komposition av l-dopa

Country Status (15)

Country Link
US (1) US4981695A (sv)
EP (1) EP0260236B1 (sv)
JP (1) JPH0662405B2 (sv)
AT (1) ATE58292T1 (sv)
CA (1) CA1298198C (sv)
DD (1) DD286107A5 (sv)
DE (1) DE3766200D1 (sv)
DK (1) DK442287A (sv)
ES (1) ES2036221T3 (sv)
FI (1) FI86689C (sv)
HU (1) HU197211B (sv)
MX (1) MX172918B (sv)
NO (1) NO176549C (sv)
PT (1) PT85591B (sv)
SE (1) SE460947B (sv)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
CA2007055A1 (en) * 1989-01-06 1990-07-06 Garth Boehm Theophylline dosage form
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US7530461B2 (en) 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US6992107B1 (en) 1995-03-10 2006-01-31 Photocure Asa Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
US6492420B2 (en) 1995-03-10 2002-12-10 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US5997831A (en) * 1996-07-12 1999-12-07 Engelhard Corporation Method of catalytically treating the atmosphere and heat exchange devices produced thereby
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
ES2280602T3 (es) * 2001-07-26 2007-09-16 Merck Patent Gmbh Uso de 2-(5-(4-fluorofenil)-3-piridilmetilaminometil)-cromano y sus sales fisiologicamente aceptables.
BR0308556A (pt) * 2002-03-21 2005-05-03 Martin C Hinnz Tecnologia de otimização do segmento de sistema de serotonina e de catecolaminas
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
EP1680083A1 (en) * 2003-10-31 2006-07-19 ALZA Corporation Compositions and dosage forms for ehnanced absorption of iron
WO2005056708A2 (en) * 2003-12-09 2005-06-23 Spherics, Inc. Bioadhesive polymers with catechol functionality
US20080311191A1 (en) * 2004-08-27 2008-12-18 Avinash Nangia Multi-Layer Tablets and Bioadhesive Dosage Forms
WO2007002516A2 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
US20070275060A1 (en) * 2005-08-05 2007-11-29 Osmotica Costa Rica Sociedad Anonima Extended release solid pharmaceutical composition containing carbidopa and levodopa
WO2007084383A2 (en) * 2006-01-13 2007-07-26 University Of South Carolina Method and composition for the treatment of parkinson's disease
US20100226855A1 (en) * 2006-03-02 2010-09-09 Spherics, Inc. Rate-Controlled Oral Dosage Formulations
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1116256A (fr) * 1954-12-09 1956-05-07 Stylographe à bille
DE1128461B (de) * 1959-01-15 1962-04-26 Fernseh Gmbh Einrichtung zum Schutz einer Fernsehaufnahmeroehre gegen Fehl-bedienung ihrer motorisch angetriebenen Lichtstromregeleinrichtung
FR2116256A1 (en) * 1970-12-02 1972-07-13 Sobio Lab Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects
JPS5518694B2 (sv) * 1973-04-02 1980-05-21
DE2343218C2 (de) * 1973-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Furosemid enthaltende Pellets
DE2513940A1 (de) * 1975-03-29 1976-10-14 Merck Patent Gmbh Pharmazeutische zubereitung
DE2655331A1 (de) * 1976-12-07 1978-06-08 Hoechst Ag Zubereitungsformen von 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoesaeure und verfahren zu ihrer herstellung
JPS5436645A (en) * 1977-08-29 1979-03-17 Omron Tateisi Electronics Co Temperature control system for boiler
CH627077A5 (en) * 1978-01-01 1981-12-31 Sankyo Co Pharmaceutical composition which foams in the intestine
CH649216A5 (de) * 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4446138A (en) * 1982-02-10 1984-05-01 Pack Howard M Method and composition for reducing weight
JPS59139317A (ja) * 1983-01-31 1984-08-10 Teisan Seiyaku Kk 持続性のニフエジピン製剤
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa

Also Published As

Publication number Publication date
JPH0662405B2 (ja) 1994-08-17
DE3766200D1 (de) 1990-12-20
ATE58292T1 (de) 1990-11-15
MX172918B (es) 1994-01-21
NO176549B (no) 1995-01-16
SE8603582D0 (sv) 1986-08-26
FI86689B (fi) 1992-06-30
DK442287A (da) 1988-02-27
ES2036221T3 (es) 1993-05-16
FI873672A (fi) 1988-02-27
DK442287D0 (da) 1987-08-25
PT85591A (en) 1987-09-01
SE460947B (sv) 1989-12-11
EP0260236A1 (en) 1988-03-16
HUT44438A (en) 1988-03-28
DD286107A5 (de) 1991-01-17
PT85591B (pt) 1990-05-31
CA1298198C (en) 1992-03-31
NO873589D0 (no) 1987-08-25
FI873672A0 (fi) 1987-08-25
NO176549C (no) 1995-04-26
US4981695A (en) 1991-01-01
FI86689C (sv) 1992-10-12
JPS63139128A (ja) 1988-06-10
NO873589L (no) 1988-02-29
HU197211B (en) 1989-03-28
EP0260236B1 (en) 1990-11-14

Similar Documents

Publication Publication Date Title
SE8603582L (sv) Komposition innehallande l-dopa
YU174490A (sh) Novi estri tienil-karboksilne kiseline sa aminoalkoholima, njihova kvaterna jedinjenja kao i pripremanje i primena tih jedinjenja
FI925100A0 (fi) Substituerade bifenylpyridoner
BG60102B2 (bg) Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол
SE8502950L (sv) Ny galenisk retardform
PL268927A1 (en) Method of obtaining novel derivatives of benzimidazole
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
SE8700137D0 (sv) Diuretisk komposition
PT90308A (pt) Processo para a preparacao de composicoes farmaceuticas contendo azelastina com libertacao controlada da substancia activa
SE8803583L (sv) Farmaceutisk komposition
DE3764235D1 (de) Ifosfamid-lyophilisat und verfahren zu dessen herstellung.
NO883520D0 (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
SE8701077D0 (sv) Pharmaceutical composition
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
JPS537684A (en) Optical active lactam derivatives and their preparation
SU1387399A1 (ru) Питательная среда для культивирования лептоспир

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8603582-1

Effective date: 19920306

Format of ref document f/p: F